1H-吲唑-3-乙腈 | 101714-15-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 1H-吲唑-3-乙腈
• 英文名称: 2-(1H-indazol-3-yl)acetonitrile
• 英文别名: 2-(2H-indazol-3-yl)acetonitrile
• CAS: 101714-15-2
• 化学式: C₉H₇N₃
• 分子量: 157.175
• InChiKey: LCCXBLLWPANQHU-UHFFFAOYSA-N

物化性质

• 熔点：
  75 °C(Solv: benzene (71-43-2); ligroine (8032-32-4))
• 沸点：
  220 °C(Press: 1 Torr)
• 密度：
  1.295±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  52.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1H-吲唑-3-乙腈 在 盐酸 、 lithium aluminium tetrahydride 、 偶氮二甲酸二异丙酯 、 水 、 三苯基膦 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 1.5h， 生成
  参考文献：
  名称：

  Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase

  摘要：

  Next generation NNRTIs are sought which possess both broad spectrum antiviral activity against key mutant strains and a high genetic barrier to the selection of new mutant viral strains. Pyridones were evaluated as an acyclic conformational constraint to replace the aryl ether core of MK-4965 (1) and the more rigid indazole constraint of MK-6186 (2). The resulting pyridone compounds are potent inhibitors of HIV RT and have antiviral activity in cell culture that is superior to other next generation NNRTI's. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.027
• 作为产物：
  描述：

  吲哚 在 盐酸 、 sodium tetrahydroborate 、 水 、 sodium nitrite 作用下， 以 1,4-二氧六环 、 甲醇 、 formamide 为溶剂， 反应 18.25h， 生成 1H-吲唑-3-乙腈
  参考文献：
  名称：

  Discovery of the cancer cell selective dual acting anti-cancer agent (Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitrile (A131)

  摘要：

  Selective targeting of cancer cells over normal cells is a key objective of targeted therapy. However few approaches achieve true mechanistic selectivity resulting in debilitating side effects and dose limitation. In this work we describe the discovery of A131 (4a), a new agent with an unprecedented dual mechanism of action targeting both mitosis and autophagy. Compound 4a was first identified in a phenotypic screen in which HeLa cells treated with 4a manifested mitotic arrest along with formation of multiple vesicles. Further investigations showed that 4a causes an increase in mitotic marker pH3 and autophagy marker LC3. Importantly 4a induces cell death in cancer cells while sparing normal cells which regrow after 4a is removed. Dual activities against pH3 and LC3 markers are required for cancer cell selectivity. An extensive SAR investigation confirmed 4a as the optimal dual inhibitor with potency against a panel of 30 cancer cell lines (average antiproliferative GI(50) 1.5 mu M). In a mouse model of paclitaxel-resistant colon cancer, 4a showed 74% tumor growth inhibition when administered at a dose of 20 mg/kg IP twice a day. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.07.011

文献信息

• Tryptamine Synthesis by Iron Porphyrin Catalyzed C−H Functionalization of Indoles with Diazoacetonitrile
  作者：Katharina J. Hock、Anja Knorrscheidt、Renè Hommelsheim、Junming Ho、Martin J. Weissenborn、Rene M. Koenigs

  DOI：10.1002/anie.201813631

  日期：2019.3.11

  non‐precious metal catalysts is an important research area for the development of efficient and sustainable processes. Herein, we describe the development of iron porphyrin catalyzed reactions of diazoacetonitrile with N‐heterocycles yielding important precursors of tryptamines, along with experimental mechanistic studies and proof‐of‐concept studies of an enzymatic process with YfeX enzyme. By using readily

  非贵金属催化剂对CH键的功能化是开发高效和可持续工艺的重要研究领域。在本文中，我们描述了铁卟啉催化的重氮乙腈与N-杂环反应产生重要的色胺的前体的反应，以及用YfeX酶进行酶促过程的实验机理研究和概念验证研究。通过使用现成的FeTPPC1，我们实现了吲哚和吲唑杂环的高效CH功能化。这些转化具有温和的反应条件，出色的收率和宽泛的官能团耐受性，可在克规模上进行，因此可提供独特的流线型获取色胺的途径。
• [EN] SELECTIVE ANTI-CANCER COMPOUNDS<br/>[FR] COMPOSÉS ANTI-CANCÉREUX SÉLECTIFS
  申请人：NAT UNIV SINGAPORE

  公开号：WO2016200339A1

  公开（公告）日：2016-12-15

  A compound of formula I, wherein the compound of formula I has the structure: wherein R1 to R5, Y, L, Z and X1 to X7 have meanings given in the description, said compounds having utility in the treatment of hyperproliferative disease.

  式I的化合物，其中该化合物具有以下结构：其中R1至R5，Y，L，Z和X1至X7的含义如描述中所示，这些化合物在治疗过度增殖性疾病方面具有用途。
• Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents
  申请人：Rondot Benoit

  公开号：US20090023779A1

  公开（公告）日：2009-01-22

  The present invention relates to compounds of formula (I): in which R 1 , R 2 , R 3 , X, Y and A are as defined in the specification. The compounds are modulators of the estrogen receptors.

  本发明涉及到式（I）的化合物：其中R1、R2、R3、X、Y和A如规范中所定义。这些化合物是雌激素受体的调节剂。
• Kinase inhibitors
  申请人：Chan Tin-Yau

  公开号：US20080004257A1

  公开（公告）日：2008-01-03

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease.

  具有公式（I）一般结构的化合物，或其药学上可接受的盐、溶剂或酯，可用于治疗免疫缺陷、癌症、心血管疾病、内分泌紊乱、帕金森病、代谢性疾病、肿瘤发生、阿尔茨海默病、心脏病、糖尿病、神经退行性疾病、炎症、肾脏疾病、动脉硬化和气道疾病等疾病、障碍或状况的治疗。
• INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS
  申请人：RONDOT Benoit

  公开号：US20110237624A1

  公开（公告）日：2011-09-29

  The present invention relates to compounds of formula (I): in which R 1 , R 2 , R 3 , X, Y and A are as defined in the specification. The compounds are modulators of the estrogen receptors.

  本发明涉及公式（I）的化合物：其中R1，R2，R3，X，Y和A如规范中所定义。这些化合物是雌激素受体的调节剂。